Skip to main content

Dexcom Issues Statement on Recent Market Speculation

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

DexCom, Inc. (NASDAQ: DXCM) today issued the following statement in response to recent media and market speculation:

“Like many companies, Dexcom’s Board and management team regularly review opportunities to enhance stockholder value and create benefits for customers, including through mergers and acquisitions. It is generally our policy not to comment on rumors or speculation, however, in light of recent sustained media and market speculation as well as the upcoming American Diabetes Association conference, we wish to confirm that Dexcom is not in active discussions regarding a merger transaction at this time. We do not intend to comment further on this topic and we assume no obligation to make any further announcement or disclosure should circumstances change.”

About DexCom, Inc.

DexCom, Inc. empowers people to take control of diabetes through innovative continuous glucose monitoring (CGM) products. Headquartered in San Diego, California, Dexcom has emerged as a leader of diabetes care technology. By listening to the needs of patients, caregivers, and clinicians, Dexcom simplifies and improves diabetes management around the world.

Contacts

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Recent Quotes

View More
Symbol Price Change (%)
AMZN  249.13
+0.63 (0.26%)
AAPL  264.03
-2.40 (-0.90%)
AMD  273.16
+15.04 (5.83%)
BAC  53.74
-0.58 (-1.06%)
GOOG  332.64
-1.83 (-0.55%)
META  674.38
+2.80 (0.42%)
MSFT  419.26
+8.04 (1.96%)
NVDA  198.13
-0.74 (-0.37%)
ORCL  177.65
+7.84 (4.61%)
TSLA  387.48
-4.47 (-1.14%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.